Day 1 :
Metabolomics NMRS Core, Mayo Clinic, USA
Time : 09:01-09:30
Petras Dzeja has completed his PhD from Kaunas Medical University, Lithuania and postdoctoral studies from Department of Biochemistry, University of Minnesota, Minneapolis MN, USA. He is the Co-director of Metabolomics NMRS Core, at Mayo Clinic, Rochester MN, a world renown Medical Center. Metabolomics NMRS Core is part of Mayo Clinic Metabolomics Resource Center which is one of six metabolomics cores in USA funded by NIH. Dr. Dzeja has developed 18O-assisted 31P NMR and mass spectrometric phosphometabolomics technology and pioneered phosphotransfer network, phosphometabolomics and system bioenergetics concepts. He has published more than 80 papers in reputed journals and has been serving on editorial board of PLOS ONE as a metabolomics expert.
Evaluation of metabolomics phenotypes requires knowledge not only metabolite levels but also their turnover rates from which metabolic fluxes and status of the whole metabolic system can be deducted. In this regard, stable isotope 18O-based metabolite tagging technology provides quantitative measurements of metabolite levels and turnover rates of many metabolites which metabolism include water as a reactant, most notably phosphometabolites, amino and organic acids. Using this technology dynamics of over 10 major metabolic and signaling pathways can be tracked simultaneously, including ATP turnover, oxidative phosphorylation, glycolysis/glycogenolysis, Krebs and urea cycles pentose phosphate pathway and phosphotransfer reactions. The 18O labeling methodology is based on the incorporation of the 18O nuclei (from H218O), into metabolite group with each act of enzymatic reaction, and subsequent distribution of 18O-labeled groups among different molecules. Using this approach major metabolites and their turnover rates can be quantified in cells and tissue samples and whole blood by 18O-assisted 31P NMR and 1H NMR spectroscopy and mass spectrometry. In this way obtained dynamic metabolomics profile appears to be sensitive indicator of energy and metabolic imbalances like the ones created by genetic deficiencies, myocardial ischemia, heart failure, aging and neurodegenerative disorders. Thus, 18O-assisted 31P NMR/mass spectrometry is a valuable tool for phosphometabolomic and fluxomic profiling of transgenic models of human diseases revealing system-wide adaptations in metabolic networks, as well as for biomarker identification in human diseases and metabolic monitoring of treatment efficacy and drug toxicity.
Tulane University, USA
Time : 09:31-10:00
Dr. Lu Qi has completed his PhD from Tufts University and postdoctoral studies from Harvard University School of Public Health. He is Regents Distinguished Chair and Professor; and Director of Tulane University Obesity Research Center. He has published more than 190 papers in reputed journals and has been serving as Editor-in-Chief and an editorial board member for several journals.
Plasma branched-chain amino acids (BCAAs, including leucine, isoleucine, and valine) were recently related to risk of type 2 diabetes (T2D). We assessed associations between cumulative consumption of BCAAs and risk of T2D among participants from three prospective cohorts: the Nurses’ Health Study (NHS; followed from 1980 to 2012), NHS II (followed from 1991 to 2011), and the Health Professionals Follow-up Study (HPFS; followed from 1986 to 2010). rnWe found higher total BCAA intake was associated with an increased risk of T2D in men and women. Recently, we examined the effects of weight-loss diets on long-term changes in plasma amino acids and the associations of these changes with weight loss and the improvement of insulin resistance in 2 randomized clinical trials, POUNDS LOST and DIRECT. In both trials, weight loss was directly related to the concurrent reduction of the BCAAs leucine and isoleucine and aromatic amino acid (AAA) tyrosine. In addition, we showed that reduction in AAA tyrosine was significantly related to improved insulin resistance, independent of weight loss, in both trials.rn